OR WAIT null SECS
UBM Americas
Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.
November 05, 2012
USP revises labeling requirements for Heparin.
November 04, 2012
FDA has pushed back goals in relation to the Prescription Drug User Fee Act (PDUFA), the Biosimilar User Fee Act (BsUFA), and Medical Device User Fee Act (MDUFA) as a result of the closing of agency offices during Hurricane Sandy.
October 17, 2012
The recent presidential and vice-presidential debates have highlighted the need for strategies for economic growth in the US, including the roles innovation and trade play in stimulating the US economy.
September 27, 2012
An upcoming PharmTech Viewpoint article (Check out PharmTech’s October issue) raises that very question.
September 13, 2012
In 2008, adverse affects and deaths linked to Baxter’s blood thinner drug heparin revealed contamination in the heparin supply chain originating from an API manufacturer in China. FDA identified oversulfated chondroitin sulfate (OSCS) in the contaminated heparin.